BTS/SIGN, NICE and GINA guidelines recommend that patients should be on the lowest effective dose of ICS that controls their asthma.1 – 3
The FFLUX study compared the effectiveness of switching adult patients controlled on Seretide® Evohaler® 250µg to flutiform 250µg.4
FFLUX was a pragmatic, open-label, randomised, non-inferiority trial that assessed the effectiveness of switching and stepping down to flutiform, with asthma control assessed according to ACQ7.4
Patients either remained on Seretide® Evohaler® 250/25µg, or were changed to flutiform 250/10µg. For phase II of the trial, 116 patients controlled on flutiform 250/10µg either remained on flutiform 250/10µg, or were stepped down to flutiform 125/5µg.
Patients who stepped across from Seretide® Evohaler® 250/25 µg to flutiform 250/10 µg experienced:
Controlled patients who stepped down to flutiform 125/5µg:
*The non-inferiority limit on the ACQ7 (7 item asthma control questionnaire) was set at 0.3
For more information on the latest evidence and guidance on stepping down treatment in asthma, view this EDUCATIONAL WEBINAR